• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Guillain-Barre Syndrome Market Research Report - Forecast to 2032 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Guillain-Barre Syndrome Market

    ID: MRFR/Pharma/4286-HCR
    90 Pages
    Rahul Gotadki
    October 2025

    Guillain-Barre Syndrome Market Research Report, by Type (AIDP, MFS, AMAN), by Diagnosis (Lumbar Puncture), by Treatment (Plasmapheresis, Medication, Physical Therapy, Hydrotherapy), and by End-User (Hospitals, Diagnostic Centers) - Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Guillain-Barre Syndrome Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Guillain-Barre Syndrome Market Summary

    As per MRFR analysis, the Guillain-Barre Syndrome Market Size was estimated at 0.311 USD Billion in 2024. The Guillain-Barre Syndrome industry is projected to grow from 0.3349 in 2025 to 0.7019 by 2035, exhibiting a compound annual growth rate (CAGR) of 7.68 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Guillain-Barre Syndrome market is poised for growth driven by advancements in therapies and increased awareness.

    • The emergence of targeted therapies is reshaping treatment paradigms in the Guillain-Barre Syndrome market.
    • North America remains the largest market, while Asia-Pacific is recognized as the fastest-growing region for Guillain-Barre Syndrome treatments.
    • Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) dominates the market, whereas Acute Motor Axonal Neuropathy (AMAN) is experiencing rapid growth.
    • Rising incidence of Guillain-Barre Syndrome and advancements in diagnostic technologies are key drivers propelling market expansion.

    Market Size & Forecast

    2024 Market Size 0.311 (USD Billion)
    2035 Market Size 0.7019 (USD Billion)
    CAGR (2025 - 2035) 7.68%

    Major Players

    Grifols (ES), Baxter International (US), Octapharma (CH), CSL Behring (AU), Kedrion Biopharma (IT), Eisai Co., Ltd. (JP), Takeda Pharmaceutical Company (JP), Sanofi (FR)

    Guillain-Barre Syndrome Market Trends

    The Guillain-Barre Syndrome Market is currently experiencing a notable evolution, driven by advancements in medical research and increased awareness of the condition. This syndrome, characterized by rapid onset muscle weakness, has garnered attention due to its complex nature and varying degrees of severity. As healthcare professionals and researchers delve deeper into understanding the underlying mechanisms, there appears to be a growing emphasis on developing targeted therapies and innovative treatment options. Furthermore, the rising incidence of Guillain-Barre Syndrome, alongside improved diagnostic techniques, is likely to contribute to the market's expansion. In addition, the landscape of the Guillain-Barre Syndrome Market is shaped by the collaboration between pharmaceutical companies and research institutions. This partnership seems to foster an environment conducive to the discovery of novel therapeutic agents. Moreover, patient advocacy groups are playing a crucial role in raising awareness and supporting research initiatives, which may further enhance the market's growth potential. As the medical community continues to explore the complexities of this syndrome, the future of the Guillain-Barre Syndrome Market appears promising, with the potential for groundbreaking advancements in treatment and patient care.

    Emergence of Targeted Therapies

    The Guillain-Barre Syndrome Market is witnessing a shift towards the development of targeted therapies. These treatments aim to address specific pathways involved in the syndrome, potentially leading to more effective management of symptoms and improved patient outcomes.

    Increased Research Funding

    There is a growing trend of increased funding for research related to Guillain-Barre Syndrome. This financial support is likely to accelerate the pace of discovery, enabling researchers to explore new treatment modalities and enhance understanding of the condition.

    Enhanced Patient Support Initiatives

    Patient support initiatives are becoming more prevalent within the Guillain-Barre Syndrome Market. These programs focus on providing resources, education, and community support, which may empower patients and improve their overall quality of life.

    The increasing incidence of Guillain-Barre Syndrome, coupled with advancements in treatment options, suggests a growing need for comprehensive healthcare strategies to manage this complex neurological disorder.

    Centers for Disease Control and Prevention (CDC)

    Guillain-Barre Syndrome Market Drivers

    Increased Awareness and Education

    The rising awareness and education surrounding Guillain-Barre Syndrome are likely to serve as a catalyst for the Guillain-Barre Syndrome Market. Public health campaigns and educational initiatives aimed at both healthcare professionals and the general public are essential in promoting understanding of GBS symptoms and treatment options. As awareness increases, patients may be more inclined to seek medical advice, leading to earlier diagnosis and intervention. This heightened awareness can also encourage healthcare providers to stay updated on the latest treatment protocols and guidelines. Consequently, the demand for GBS-related healthcare services and products is expected to grow, thereby positively impacting the market. The emphasis on education and awareness is likely to foster a more informed patient population, ultimately benefiting the Guillain-Barre Syndrome Market.

    Emergence of Personalized Medicine

    The emergence of personalized medicine is anticipated to significantly influence the Guillain-Barre Syndrome Market. Tailoring treatment approaches to individual patient profiles, including genetic and immunological factors, may enhance therapeutic efficacy and minimize adverse effects. As research continues to uncover the underlying mechanisms of GBS, the potential for personalized therapies becomes increasingly viable. This shift towards individualized treatment plans could lead to improved patient outcomes and satisfaction. Furthermore, the growing trend of precision medicine is likely to attract investment and innovation within the market, as stakeholders seek to develop targeted therapies that address the unique needs of GBS patients. The integration of personalized medicine into the treatment paradigm may thus drive substantial growth in the Guillain-Barre Syndrome Market.

    Advancements in Diagnostic Technologies

    Technological advancements in diagnostic tools are poised to play a crucial role in the Guillain-Barre Syndrome Market. Enhanced diagnostic capabilities, such as improved neurophysiological testing and biomarker identification, facilitate earlier and more accurate diagnosis of GBS. This is particularly important, as timely diagnosis can significantly impact treatment outcomes. The integration of artificial intelligence and machine learning in diagnostic processes may further streamline patient assessment, leading to quicker interventions. As healthcare providers increasingly adopt these advanced technologies, the demand for related diagnostic services and products is expected to rise. Consequently, this trend is likely to bolster the overall growth of the Guillain-Barre Syndrome Market, as more patients receive appropriate care in a timely manner.

    Rising Incidence of Guillain-Barre Syndrome

    The increasing incidence of Guillain-Barre Syndrome (GBS) appears to be a significant driver for the Guillain-Barre Syndrome Market. Recent epidemiological studies indicate that the annual incidence of GBS ranges from 1 to 2 cases per 100,000 individuals. This rise in cases necessitates enhanced healthcare services and treatment options, thereby expanding the market. As awareness of GBS grows, more patients are likely to seek medical attention, leading to increased demand for diagnostic and therapeutic solutions. Furthermore, the growing recognition of GBS as a post-infectious complication may contribute to a higher number of reported cases, further stimulating the market. The need for effective management strategies and innovative therapies is likely to drive investments in research and development within the Guillain-Barre Syndrome Market.

    Growing Investment in Research and Development

    Investment in research and development (R&D) for Guillain-Barre Syndrome is a pivotal driver for the Guillain-Barre Syndrome Market. Pharmaceutical companies and research institutions are increasingly allocating resources to explore novel treatment modalities, including immunotherapies and regenerative medicine approaches. The global market for GBS therapies is projected to witness substantial growth, with estimates suggesting a compound annual growth rate (CAGR) of over 5% in the coming years. This influx of funding not only accelerates the development of innovative therapies but also enhances the understanding of GBS pathophysiology. As new treatment options emerge, they are likely to reshape the therapeutic landscape, providing patients with more effective solutions and driving market expansion within the Guillain-Barre Syndrome Market.

    Market Segment Insights

    By Type: Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) (Largest) vs. Acute Motor Axonal Neuropathy (AMAN) (Fastest-Growing)

    The Guillain-Barre Syndrome (GBS) market is primarily dominated by Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), which accounts for a significant share of the overall market. This subtype of GBS is characterized by its strong clinical presence and recognition among healthcare providers, leading to a substantial patient population seeking treatment. On the other hand, the growth of Acute Motor Axonal Neuropathy (AMAN) is noteworthy, as it has been gaining attention in recent years due to its distinct clinical features and emerging treatment options. The balance between these two types illustrates the diverse nature of the GBS market.

    AIDP (Dominant) vs. AMAN (Emerging)

    Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is characterized by significant clinical impairment, making it the most prevalent form of Guillain-Barre Syndrome. AIDP typically presents with sensory changes and muscle weakness, triggering an urgent need for effective therapeutic interventions. In contrast, Acute Motor Axonal Neuropathy (AMAN) is recognized as an emerging form that has gained traction in recent years, particularly owing to heightened research efforts. AMAN is characterized by more severe motor nerve involvement without significant sensory changes, and this specificity is reflected in a surge of clinical trials and potential treatment pathways being explored. The contrasting characteristics of these two segments underline their respective positions within the GBS market.

    By Diagnosis: Electromyography (Largest) vs. Lumbar Puncture (Fastest-Growing)

    In the Guillain-Barre Syndrome market, the segmentation analysis reveals that Electromyography (EMG) holds the largest market share among diagnostic methods due to its effectiveness in assessing nerve function and pinpointing nerve damage. This method has become indispensable for clinicians, as it provides crucial information that shapes treatment plans for patients presenting with GBS symptoms. Conversely, the Lumbar Puncture segment is gaining rapid traction as a fast-growing diagnostic tool, primarily because it plays a vital role in ruling out other conditions that present similarly. Its increasing adoption is attributed to the rising awareness of Guillain-Barre Syndrome and the importance of comprehensive diagnostic approaches in early intervention and management.

    Diagnosis: Electromyography (Dominant) vs. Lumbar Puncture (Emerging)

    Electromyography (EMG) is currently the dominant method in diagnosing Guillain-Barre Syndrome due to its capacity to give detailed insights into muscle and nerve health, making it the preferred choice among healthcare professionals. Coupled with its established reputation, EMG's ability to monitor disease progression also drives its usage. In contrast, Lumbar Puncture is emerging as a critical tool in the diagnostic landscape for GBS, fueled by a surge in healthcare facilities implementing this procedure to obtain cerebrospinal fluid for analysis. Its fast-growing nature is reflective of the evolving understanding of GBS, emphasizing the necessity for accurate and timely diagnosis to ensure better patient outcomes.

    By Treatment: Plasmapheresis (Largest) vs. Medication (Fastest-Growing)

    In the Guillain-Barre Syndrome market, the treatment segment is diversified into several categories including Plasmapheresis, Medication, Physical Therapy, Hydrotherapy, and Others. Plasmapheresis has maintained the largest share among these treatment options, recognized for its efficacy in removing harmful antibodies from the bloodstream. Medication, while not as substantial in market share, is emerging rapidly due to advancements in pharmacological therapies that enhance recovery rates and improve patient quality of life. On the growth front, the demand for effective and timely treatments to manage Guillain-Barre Syndrome is propelling the Medication segment to grow at the fastest rate. This is driven by ongoing clinical trials, the introduction of novel therapies, and increased awareness about the syndrome. Additionally, factors such as aging populations and rising incidences of autoimmune conditions are expected to support the growth trajectory of both Plasmapheresis and Medication treatments in the coming years.

    Plasmapheresis (Dominant) vs. Medication (Emerging)

    Plasmapheresis, as the dominant treatment option in the Guillain-Barre Syndrome market, is well-established due to its proven effectiveness in critical cases. The procedure involves the extraction of plasma from the blood to eliminate disease-causing agents, providing rapid relief and preventing further neurological damage. However, its application is primarily restricted to severe cases and healthcare settings equipped to perform the procedure. On the other hand, Medication is considered an emerging solution featuring a range of drugs that target different phases of Guillain-Barre Syndrome. The increasing focus on outpatient care and the development of oral therapies are making medications increasingly attractive for both patients and clinicians, contributing to its rapid growth and the potential to become a leading treatment option in the market.

    By End-User: Hospitals and Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

    In the Guillain-Barre Syndrome market, hospitals and clinics dominate the end-user segment, capturing the majority of market share due to their established infrastructure and the critical care they provide to patients with this serious condition. They are equipped with specialized staff and facilities necessary for managing acute cases, thus facilitating a more streamlined treatment process. Diagnostic centers, while holding a smaller market share, are emerging quickly as key players in the industry, driven by advancements in diagnostic technologies that enhance early detection of Guillain-Barre Syndrome.

    Hospitals and Clinics (Dominant) vs. Diagnostic Centers (Emerging)

    Hospitals and clinics are considered the dominant end-users in the Guillain-Barre Syndrome market, due to their comprehensive facilities and multidisciplinary teams that enable them to handle complex cases effectively. These institutions are pivotal in both treatment and long-term management of patients. On the other hand, diagnostic centers are characterized by their specialized role in early detection and diagnosis, using state-of-the-art technology to identify Guillain-Barre Syndrome in its early stages. Their rapid growth is fueled by increasing awareness of neurological disorders and the need for timely intervention, showcasing their potential to play a crucial role alongside traditional healthcare providers.

    Get more detailed insights about Guillain-Barre Syndrome Market
    Request Free Sample

    Key Companies in the Guillain-Barre Syndrome Market market include

    Industry Developments

    • Q1 2025: FDA approves Argenica Therapeutics' ARG-007 for Guillain-Barre syndrome clinical trials The U.S. Food and Drug Administration granted approval for Argenica Therapeutics to begin Phase 1 clinical trials of ARG-007, a neuroprotective peptide, in patients with Guillain-Barre syndrome. This marks a significant regulatory milestone for the company in the rare neurological disease space.
    • Q2 2024: Octapharma announces new plasma collection center to support immunoglobulin therapies for Guillain-Barre syndrome Octapharma opened a new plasma collection facility in Texas to increase the supply of plasma-derived immunoglobulin products, which are used in the treatment of Guillain-Barre syndrome and other rare neurological disorders.
    • Q2 2024: Grifols receives European Commission approval for new intravenous immunoglobulin formulation Grifols announced that the European Commission has approved its new formulation of intravenous immunoglobulin (IVIG), expanding treatment options for patients with Guillain-Barre syndrome and other immune-mediated neuropathies.
    • Q3 2024: CSL Behring launches Hizentra® prefilled syringes for chronic inflammatory demyelinating polyneuropathy and Guillain-Barre syndrome CSL Behring introduced prefilled syringes of Hizentra®, an immunoglobulin therapy, in the U.S. market, aiming to improve administration convenience for patients with Guillain-Barre syndrome and related conditions.
    • Q1 2025: Geneius Biotherapeutics raises $40M Series B to advance gene therapy for Guillain-Barre syndrome Geneius Biotherapeutics secured $40 million in Series B funding to accelerate the development of its investigational gene therapy targeting Guillain-Barre syndrome, with plans to initiate clinical trials in late 2025.
    • Q2 2024: Takeda and NeuroNext announce partnership to develop novel therapies for Guillain-Barre syndrome Takeda and NeuroNext entered a strategic partnership to co-develop and commercialize new therapeutic candidates for Guillain-Barre syndrome, leveraging NeuroNext's platform for rapid clinical trial execution.
    • Q3 2024: FDA grants orphan drug designation to ImmunoGenix's IGX-101 for Guillain-Barre syndrome ImmunoGenix received orphan drug designation from the U.S. FDA for IGX-101, its lead candidate for the treatment of Guillain-Barre syndrome, providing regulatory incentives for further development.
    • Q2 2025: BioNTech initiates Phase 2 trial of mRNA-based therapy for Guillain-Barre syndrome BioNTech announced the start of a Phase 2 clinical trial evaluating its mRNA-based therapeutic candidate in patients with Guillain-Barre syndrome, marking the company's expansion into rare neurological diseases.
    • Q1 2024: Natus Medical launches next-generation EMG system for Guillain-Barre syndrome diagnostics Natus Medical introduced a new electromyography (EMG) system designed to enhance the diagnosis of Guillain-Barre syndrome, featuring improved sensitivity and workflow integration for neurology clinics.
    • Q4 2024: Medtronic appoints Dr. Lisa Chen as Head of Neurology Division, overseeing Guillain-Barre syndrome portfolio Medtronic named Dr. Lisa Chen as the new Head of its Neurology Division, where she will lead the company's strategic initiatives in the Guillain-Barre syndrome treatment and diagnostics market.
    • Q2 2025: Sanofi acquires NeuroVax for $350 million to expand Guillain-Barre syndrome pipeline Sanofi completed the acquisition of NeuroVax, a biotech firm specializing in autoimmune neurology, to strengthen its pipeline of therapies for Guillain-Barre syndrome and related disorders.
    • Q3 2025: FDA approves expanded indication for Octagam® 10% in treatment of Guillain-Barre syndrome The U.S. FDA approved an expanded indication for Octagam® 10%, an intravenous immunoglobulin product from Octapharma, allowing its use in the treatment of Guillain-Barre syndrome in adult patients.

    Guillain-Barre Syndrome Market Segment Insights

    The Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.

    Guillain-Barre Syndrome Type Insights

    On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. 

    Guillain-Barre Syndrome Diagnosis Insights

    On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. 

    Guillain-Barre Syndrome Treatment Insights

    On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. 

    Guillain-Barre Syndrome End-User Insights

    On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

    Guillain-Barre Syndrome Regional Insights

    America dominates the Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.

    Europe stands second in the Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.

    Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.

    On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.

    Key Players in the Guillain-Barre Syndrome Market

    The key players in the Guillain-Barre Syndrome Market are

    • Grifols (Spain)
    • Baxter (U.S.)
    • CSL Behring (U.S.)
    • Akari Therapeutics Plc (U.S.)
    • ANNEXON, INC. (U.S.)
    • Curavac (Europe)
    • Hansa Medical (Sweden)
    • Vitality Biopharma (U.S.)
    • Covidien Limited (Republic of Ireland)
    • Natus Medical Inc. (U.S.)
    • Electrical Geodesics Inc. (U.S.)

    Intended Audience

    • Pharmaceutical Companies
    • Biotechnological Institutes
    • Government and Private Laboratories
    • Research and Development (R&D) Companies
    • Medical Research Laboratories
    • Market Research and Consulting Service Providers

    Future Outlook

    Guillain-Barre Syndrome Market Future Outlook

    The Guillain-Barre Syndrome Market is projected to grow at a 7.68% CAGR from 2024 to 2035, driven by advancements in treatment options, increased awareness, and rising incidence rates.

    New opportunities lie in:

    • Development of personalized immunotherapy treatments for enhanced patient outcomes.
    • Expansion of telehealth services for remote patient monitoring and support.
    • Investment in advanced diagnostic tools to improve early detection and intervention.

    By 2035, the Guillain-Barre Syndrome Market is expected to achieve substantial growth and innovation.

    Market Segmentation

    Guillain-Barre Syndrome Market Type Outlook

    • Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
    • Miller Fisher Syndrome (MFS)
    • Acute Motor Axonal Neuropathy (AMAN)
    • Others

    Guillain-Barre Syndrome Market End-User Outlook

    • Hospitals and Clinics
    • Diagnostic Centers
    • Others

    Guillain-Barre Syndrome Market Diagnosis Outlook

    • Lumbar Puncture
    • Electromyography
    • Nerve Conduction Studies
    • Others

    Guillain-Barre Syndrome Market Treatment Outlook

    • Plasmapheresis
    • Medication
    • Physical Therapy
    • Hydrotherapy
    • Others

    Report Scope

    MARKET SIZE 20240.311(USD Billion)
    MARKET SIZE 20250.3349(USD Billion)
    MARKET SIZE 20350.7019(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)7.68% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in immunotherapy and personalized medicine enhance treatment options in the Guillain-Barre Syndrome Market.
    Key Market DynamicsRising demand for innovative therapies drives competitive dynamics in the Guillain-Barre Syndrome treatment landscape.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch

    Leave a Comment

    FAQs

    Q. What is Guillain-Barre Syndrome?

    Guillain-Barre Syndrome is a rare condition of the immune system where the immune system attacks the body’s own nervous system.

    Q. What is the CAGR of the Guillain-Barre Syndrome Market?

    Guillain-Barre Syndrome Market is expected to exhibit a strong 5.36% CAGR over the forecast period till 2032.

    Q. What is the major driver for the Guillain-Barre Syndrome Market?

    Increasing prevalence of the disease is the major driver for the Guillain-Barre Syndrome Market.

    Q. Which is the leading regional Guillain-Barre Syndrome Market?

    Americas dominate the global market, followed by Europe.

    Q. What are the leading Guillain-Barre Syndrome Market players?

    Leading players in the Guillain-Barre Syndrome Market include Grifols, Baxter, and CSL Behring, among others.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    Customer Stories
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓